Evotec SE (EVO) Cash from Financing Activities (2009 - 2026)
Evotec SE (EVO) reported Cash from Financing Activities of -$22349.5 for Q1 2026, down 159.97% on a YoY basis from $37267.2 in Q1 2025, and up 99.95% sequentially from -$43.8 million in Q4 2025.
Evotec SE (EVO) Cash from Financing Activities (2009 - 2026) Analysis & Trends
Evotec SE (EVO) has 9 years of Cash from Financing Activities data on file, last reported at -$22349.5 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Financing Activities fell 159.97% year-over-year to -$22349.5; the trailing twelve-month figure through Mar 2026 stood at -$43.9 million (up 74.56% YoY), and the FY2025 full-year result was -$43.8 million, up 74.61% from the prior year.
- Cash from Financing Activities rose to -$22349.5 in Q1 2026, from -$43.8 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $77.4 million in Q4 2023 to a low of -$172.4 million in Q4 2024.
- A 5-year average of -$11.7 million and a median of -$7889.6 in 2024 frame the typical range for Cash from Financing Activities.
- Across the five-year window, Cash from Financing Activities surged 991.27% in 2023 and slumped 1780.81% in 2024, its largest moves.
- Tracing EVO's Cash from Financing Activities over 5 years: stood at -$59.3 million in 2022, then soared by 230.55% to $77.4 million in 2023, then sank by 322.75% to -$172.4 million in 2024, then jumped by 74.58% to -$43.8 million in 2025, then surged by 99.95% to -$22349.5 in 2026.
- Business Quant data shows EVO's Cash from Financing Activities at -$22349.5 in Q1 2026, -$43.8 million in Q4 2025, and -$14185.3 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 13.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -840.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -494.13 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -1.48 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -203.80 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -86.10 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -65.00 Mn |
| 10 | Evotec SE | 351.60 Mn | 351.08 Mn | - | -22,349.53 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -22,349.53 |
| Mar 31, 2026 | -22,349.53 |
| Dec 31, 2025 | -43.81 Mn |
| Dec 31, 2025 | -43.81 Mn |
| Sep 30, 2025 | -14,185.31 |
| Sep 30, 2025 | -14,185.31 |
| Jun 30, 2025 | -16,635.28 |
| Jun 30, 2025 | -16,635.28 |
| Mar 31, 2025 | 37,267.21 |
| Mar 31, 2025 | 37,267.21 |
| Dec 31, 2024 | -172.35 Mn |
| Dec 31, 2024 | -172.35 Mn |
| Sep 30, 2024 | -7,889.61 |
| Sep 30, 2024 | -7,889.61 |
| Jun 30, 2024 | -128,192.70 |
| Jun 30, 2024 | -128,192.70 |
| Mar 31, 2024 | -6,378.03 |
| Mar 31, 2024 | -6,378.03 |
| Dec 31, 2023 | 77.38 Mn |
| Dec 31, 2023 | 77.38 Mn |